According to a recent LinkedIn post from Hemanext, the company recently polled clinicians on whether fresher red blood cell units may function better for certain patient groups, such as those requiring chronic transfusions. The post notes that stored red cells naturally lose ATP, 2,3-DPG, and flexibility over time, potentially impacting performance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights Hemanext’s hypoxic red blood cell technology, which is described as helping preserve these qualities throughout the storage period and narrowing the functional gap between younger and older blood units, based on cited scientific data. The post further indicates that this technology underpins Hemanext ONE, presented as the first and only FDA-authorized and CE-marked hypoxic blood storage system, suggesting a differentiated position in the blood storage market.
For investors, this emphasis on clinician feedback and referenced scientific literature may point to growing clinical interest in quality-focused blood storage solutions. If adoption of hypoxic storage systems expands, Hemanext could benefit from recurring revenue streams tied to hospital and blood bank usage, while regulatory authorizations and CE marking may support broader geographic commercialization.
The post’s focus on reducing oxygen-driven degradation and improving functional consistency of red blood cell units could position the company within a premium segment of transfusion medicine. Over time, demonstrable clinical and economic benefits—such as better outcomes for chronic transfusion patients—could strengthen Hemanext’s competitive moat and enhance its strategic value in potential partnerships or acquisition scenarios.